Baidu
map

Aliment Pharmacol Ther:胃食管反流病和饮食中碳水化合物摄入量有关

2016-09-11 Seven L 译 MedSci原创

背景:非洲裔美国女性与欧裔美国女性相比,虽然肥胖率更高;但是胃食管反流病(GERD)及其合并症却在欧裔美国女性中更为普遍。随着肥胖的增加,随之而来是胰岛素抵抗,进而饮食中过量摄入大量营养素,导致女性更多的GERD患病率和更严重的病情。 目的:探究GERD是否与饮食中碳水化合物的摄入量有关,特别是膳食简单的碳水化合物摄入,以及GERD是否与胰岛素抵抗有关。 方法:研究纳入了144名肥胖女

背景:非洲裔美国女性与欧裔美国女性相比,虽然肥胖率更高;但是胃食管反流病(GERD)及其合并症却在欧裔美国女性中更为普遍。随着肥胖的增加,随之而来是胰岛素抵抗,进而饮食中过量摄入大量营养素,导致女性更多的GERD患病率和更严重的病情。

目的:探究GERD是否与饮食中碳水化合物的摄入量有关,特别是膳食简单的碳水化合物摄入,以及GERD是否与胰岛素抵抗有关。

方法:研究纳入了144名肥胖女性,在基线、以及摄入高脂肪/低碳水化合物饮食16周后,对参与者进行评估。通过症状医疗记录、药物使用情况,每周对参与者的GERD诊断和相关药物进行评估。

结果:约33.3% (N = 33)的欧裔美国女性和20.0% (N = 9)的非洲裔美国女性,在基线时就存在GERD。与GERD相关的因素有:总碳水化合物(r = 0.34, P < 0.001)、糖(r = 0.30, P = 0.005)、血糖负荷(r = 0.34, P = 0.001)和HOMAIR (r = 0.30, P = 0.004);注意,这些关联仅限于欧裔美国女性。至于高脂肪/低碳水化合物饮食,减少糖的摄入量与胰岛素抵抗的下降有关。在第10周饮食结束时,所以女性中GERD症状和药物使用情况得到缓解。

结论:GERD症状和药物使用情况在欧裔美国女性中更常见;对于这类女性,饮食中碳水化合物的摄入量、胰岛素抵抗和GERD之间存在相关性。不管怎样,高脂肪/低碳水化合物饮食可以缓解所有女性的GERD症状和药物使用情况。

原始出处:

Dietary carbohydrate intake, insulin resistance and gastro-oesophageal reflux disease: a pilot study in European- and African-American obese women.Aliment Pharmacol Ther.First published: August 2016

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (25)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2046116, encodeId=e0f6204611606, content=<a href='/topic/show?id=010b3e767b2' target=_blank style='color:#2F92EE;'>#反流病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37767, encryptionId=010b3e767b2, topicName=反流病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Dec 01 14:20:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908220, encodeId=54981908220c9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 05 00:20:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860589, encodeId=91a21860589e3, content=<a href='/topic/show?id=830b5693631' target=_blank style='color:#2F92EE;'>#摄入量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56936, encryptionId=830b5693631, topicName=摄入量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sun Jun 18 16:20:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788189, encodeId=4d7f1e88189d4, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 04 00:20:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948519, encodeId=83e719485194d, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Nov 03 13:20:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787208, encodeId=fd741e8720826, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 27 10:20:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906320, encodeId=aa94190632031, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Apr 27 20:20:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995950, encodeId=6af119959504e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Mar 06 22:20:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133577, encodeId=a18a1335e7e7, content=文章不错,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 23 15:57:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129581, encodeId=a3ae12958133, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 17 14:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2046116, encodeId=e0f6204611606, content=<a href='/topic/show?id=010b3e767b2' target=_blank style='color:#2F92EE;'>#反流病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37767, encryptionId=010b3e767b2, topicName=反流病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Dec 01 14:20:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908220, encodeId=54981908220c9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 05 00:20:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860589, encodeId=91a21860589e3, content=<a href='/topic/show?id=830b5693631' target=_blank style='color:#2F92EE;'>#摄入量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56936, encryptionId=830b5693631, topicName=摄入量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sun Jun 18 16:20:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788189, encodeId=4d7f1e88189d4, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 04 00:20:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948519, encodeId=83e719485194d, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Nov 03 13:20:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787208, encodeId=fd741e8720826, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 27 10:20:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906320, encodeId=aa94190632031, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Apr 27 20:20:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995950, encodeId=6af119959504e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Mar 06 22:20:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133577, encodeId=a18a1335e7e7, content=文章不错,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 23 15:57:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129581, encodeId=a3ae12958133, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 17 14:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2046116, encodeId=e0f6204611606, content=<a href='/topic/show?id=010b3e767b2' target=_blank style='color:#2F92EE;'>#反流病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37767, encryptionId=010b3e767b2, topicName=反流病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Dec 01 14:20:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908220, encodeId=54981908220c9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 05 00:20:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860589, encodeId=91a21860589e3, content=<a href='/topic/show?id=830b5693631' target=_blank style='color:#2F92EE;'>#摄入量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56936, encryptionId=830b5693631, topicName=摄入量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sun Jun 18 16:20:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788189, encodeId=4d7f1e88189d4, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 04 00:20:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948519, encodeId=83e719485194d, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Nov 03 13:20:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787208, encodeId=fd741e8720826, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 27 10:20:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906320, encodeId=aa94190632031, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Apr 27 20:20:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995950, encodeId=6af119959504e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Mar 06 22:20:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133577, encodeId=a18a1335e7e7, content=文章不错,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 23 15:57:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129581, encodeId=a3ae12958133, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 17 14:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=)]
    2017-06-18 lmm397
  4. [GetPortalCommentsPageByObjectIdResponse(id=2046116, encodeId=e0f6204611606, content=<a href='/topic/show?id=010b3e767b2' target=_blank style='color:#2F92EE;'>#反流病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37767, encryptionId=010b3e767b2, topicName=反流病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Dec 01 14:20:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908220, encodeId=54981908220c9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 05 00:20:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860589, encodeId=91a21860589e3, content=<a href='/topic/show?id=830b5693631' target=_blank style='color:#2F92EE;'>#摄入量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56936, encryptionId=830b5693631, topicName=摄入量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sun Jun 18 16:20:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788189, encodeId=4d7f1e88189d4, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 04 00:20:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948519, encodeId=83e719485194d, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Nov 03 13:20:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787208, encodeId=fd741e8720826, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 27 10:20:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906320, encodeId=aa94190632031, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Apr 27 20:20:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995950, encodeId=6af119959504e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Mar 06 22:20:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133577, encodeId=a18a1335e7e7, content=文章不错,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 23 15:57:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129581, encodeId=a3ae12958133, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 17 14:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2046116, encodeId=e0f6204611606, content=<a href='/topic/show?id=010b3e767b2' target=_blank style='color:#2F92EE;'>#反流病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37767, encryptionId=010b3e767b2, topicName=反流病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Dec 01 14:20:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908220, encodeId=54981908220c9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 05 00:20:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860589, encodeId=91a21860589e3, content=<a href='/topic/show?id=830b5693631' target=_blank style='color:#2F92EE;'>#摄入量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56936, encryptionId=830b5693631, topicName=摄入量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sun Jun 18 16:20:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788189, encodeId=4d7f1e88189d4, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 04 00:20:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948519, encodeId=83e719485194d, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Nov 03 13:20:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787208, encodeId=fd741e8720826, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 27 10:20:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906320, encodeId=aa94190632031, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Apr 27 20:20:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995950, encodeId=6af119959504e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Mar 06 22:20:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133577, encodeId=a18a1335e7e7, content=文章不错,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 23 15:57:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129581, encodeId=a3ae12958133, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 17 14:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2046116, encodeId=e0f6204611606, content=<a href='/topic/show?id=010b3e767b2' target=_blank style='color:#2F92EE;'>#反流病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37767, encryptionId=010b3e767b2, topicName=反流病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Dec 01 14:20:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908220, encodeId=54981908220c9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 05 00:20:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860589, encodeId=91a21860589e3, content=<a href='/topic/show?id=830b5693631' target=_blank style='color:#2F92EE;'>#摄入量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56936, encryptionId=830b5693631, topicName=摄入量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sun Jun 18 16:20:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788189, encodeId=4d7f1e88189d4, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 04 00:20:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948519, encodeId=83e719485194d, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Nov 03 13:20:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787208, encodeId=fd741e8720826, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 27 10:20:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906320, encodeId=aa94190632031, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Apr 27 20:20:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995950, encodeId=6af119959504e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Mar 06 22:20:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133577, encodeId=a18a1335e7e7, content=文章不错,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 23 15:57:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129581, encodeId=a3ae12958133, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 17 14:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=)]
    2016-11-27 jj000001
  7. [GetPortalCommentsPageByObjectIdResponse(id=2046116, encodeId=e0f6204611606, content=<a href='/topic/show?id=010b3e767b2' target=_blank style='color:#2F92EE;'>#反流病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37767, encryptionId=010b3e767b2, topicName=反流病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Dec 01 14:20:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908220, encodeId=54981908220c9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 05 00:20:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860589, encodeId=91a21860589e3, content=<a href='/topic/show?id=830b5693631' target=_blank style='color:#2F92EE;'>#摄入量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56936, encryptionId=830b5693631, topicName=摄入量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sun Jun 18 16:20:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788189, encodeId=4d7f1e88189d4, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 04 00:20:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948519, encodeId=83e719485194d, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Nov 03 13:20:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787208, encodeId=fd741e8720826, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 27 10:20:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906320, encodeId=aa94190632031, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Apr 27 20:20:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995950, encodeId=6af119959504e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Mar 06 22:20:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133577, encodeId=a18a1335e7e7, content=文章不错,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 23 15:57:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129581, encodeId=a3ae12958133, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 17 14:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2046116, encodeId=e0f6204611606, content=<a href='/topic/show?id=010b3e767b2' target=_blank style='color:#2F92EE;'>#反流病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37767, encryptionId=010b3e767b2, topicName=反流病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Dec 01 14:20:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908220, encodeId=54981908220c9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 05 00:20:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860589, encodeId=91a21860589e3, content=<a href='/topic/show?id=830b5693631' target=_blank style='color:#2F92EE;'>#摄入量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56936, encryptionId=830b5693631, topicName=摄入量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sun Jun 18 16:20:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788189, encodeId=4d7f1e88189d4, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 04 00:20:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948519, encodeId=83e719485194d, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Nov 03 13:20:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787208, encodeId=fd741e8720826, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 27 10:20:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906320, encodeId=aa94190632031, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Apr 27 20:20:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995950, encodeId=6af119959504e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Mar 06 22:20:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133577, encodeId=a18a1335e7e7, content=文章不错,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 23 15:57:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129581, encodeId=a3ae12958133, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 17 14:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=)]
    2017-03-06 yb6560
  9. [GetPortalCommentsPageByObjectIdResponse(id=2046116, encodeId=e0f6204611606, content=<a href='/topic/show?id=010b3e767b2' target=_blank style='color:#2F92EE;'>#反流病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37767, encryptionId=010b3e767b2, topicName=反流病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Dec 01 14:20:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908220, encodeId=54981908220c9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 05 00:20:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860589, encodeId=91a21860589e3, content=<a href='/topic/show?id=830b5693631' target=_blank style='color:#2F92EE;'>#摄入量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56936, encryptionId=830b5693631, topicName=摄入量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sun Jun 18 16:20:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788189, encodeId=4d7f1e88189d4, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 04 00:20:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948519, encodeId=83e719485194d, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Nov 03 13:20:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787208, encodeId=fd741e8720826, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 27 10:20:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906320, encodeId=aa94190632031, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Apr 27 20:20:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995950, encodeId=6af119959504e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Mar 06 22:20:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133577, encodeId=a18a1335e7e7, content=文章不错,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 23 15:57:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129581, encodeId=a3ae12958133, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 17 14:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=)]
    2016-09-23 1e10c84am36(暂无匿称)

    文章不错,继续学习

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2046116, encodeId=e0f6204611606, content=<a href='/topic/show?id=010b3e767b2' target=_blank style='color:#2F92EE;'>#反流病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37767, encryptionId=010b3e767b2, topicName=反流病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Dec 01 14:20:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908220, encodeId=54981908220c9, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 05 00:20:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860589, encodeId=91a21860589e3, content=<a href='/topic/show?id=830b5693631' target=_blank style='color:#2F92EE;'>#摄入量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56936, encryptionId=830b5693631, topicName=摄入量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sun Jun 18 16:20:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788189, encodeId=4d7f1e88189d4, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 04 00:20:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948519, encodeId=83e719485194d, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Nov 03 13:20:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787208, encodeId=fd741e8720826, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 27 10:20:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906320, encodeId=aa94190632031, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Apr 27 20:20:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995950, encodeId=6af119959504e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Mar 06 22:20:00 CST 2017, time=2017-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133577, encodeId=a18a1335e7e7, content=文章不错,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 23 15:57:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129581, encodeId=a3ae12958133, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 17 14:16:00 CST 2016, time=2016-09-17, status=1, ipAttribution=)]
    2016-09-17 doctorJiangchao

    继续关注

    0

相关资讯

Epidemiology:碳水化合物可不要贪吃

生命不息,生活不止。而最基本的生活元素便是“吃”、“拉”、“睡”。每一个基本元素都可以延伸出很多分支,无论是“因果论”还是“必然论”都在一定层面上说明了日常生活与健康疾病息息相关。生活方式是公共健康卫生不可回避的话题之一。全球乳腺癌发病率自20世纪70年代末开始一直呈上升趋势。美国8名妇女一生中就会有1人患乳腺癌。我国乳腺癌发病率的增长速度高出高发国家1~2个百分点。全国肿瘤登记地区乳腺癌发病率位

Schizophr Res:生酮饮食可有效地治疗精神分裂症

据来自詹姆斯库克大学的研究人员发现,高脂肪低碳水化合物的饮食可有效治疗精神分裂症,该研究结果已在线发表于Schizophrenia Research。

8种受欢迎的低碳水化合物饮食方式

8种最受欢迎的低碳水化合物饮食方式低碳水化合物饮食已经流行了很多年。它们曾经饱受争议,但是现在已经获得主流的接受度。低碳水化合物饮食较低脂饮食能更多的减轻体重,至少短期内是这样的结果。低碳水化合物饮食还可改善机体的许多健康指标,如血甘油三酯、HDL胆固醇、血糖和血压。然而,并不是所有的低碳水化合物饮食都是是一样的。它们存在很多不同的类型。这里介绍了8种最流行的低碳水化合物饮食方式:原始出处:Kri

PLOS Med:糖尿病的预防及治疗应多吃脂肪?!

近日发表于PLOS Medicine的一项新的研究表明,多吃不饱和脂肪而非碳水化合物可降低患2型糖尿病的风险。新的荟萃分析显示,将碳水化合物和饱和脂肪更换为健康的脂肪,如多不饱和脂肪,可降低血糖水平,并改善胰岛素控制。世界范围内,胰岛素抵抗和2型糖尿病的发病率正急剧上升。据CDC统计,美国约有2910万人患有糖尿病,占总人口的9.3%左右。为此,CDC呼吁人们健康饮食,定期锻炼,并使用降糖药物治疗

预防心血管疾病不仅需要节食,还需要多吃

一项新的研究指出,对于患有心血管疾病的病人,不仅要控制他们摄入饱和脂肪的量,如果能够将这部分脂肪换成高质量的碳水化合物以及非饱和脂肪(尤其是多不饱和脂肪PUFA)的摄入,将会更好的控制疾病的发生。这项囊括了127000名参与者的健康调查报告指出,每5%的饱和脂肪能量转换为等量的PUFA将伴随着25%的心血管疾病的降低。如果将同样量的单不饱和脂肪(MUFA)换成PUFA的话将会带来15%的降低。“这

Cell Metabolism:想减肥?低脂饮食效果更好

说到减肥,大家都想知道哪种饮食才是最好和最有效的饮食,既能够有效减少机体脂肪,又不会为机体带来副作用。研究人员通过比较低脂饮食和低碳水化合物饮食,他们发现,低脂饮食更能有效减少体内脂肪。研究人员进行了一项规模虽小但十分缜密的试验,在病房内选取了19名肥胖患者,观察他们两周内的体重变化情况,并将研究结果发表在Cell Metabolism杂志上。Kevin Hall是NIDDK的代谢学研究人员,他认

Baidu
map
Baidu
map
Baidu
map